Marketing approvals for generic drugs may soon be delinked from their patent status in India. This comes as a result of long-standing demand from India’s pharmaceutical industry, which depends heavily on the sale of generic drugs.
India to delink marketing authorisation and patent status
Home/Policies & Legislation | Posted 07/01/2011 0 Post your comment
The health ministry is planning to remove a question on the patent status of a drug from the form that medicine companies fill in when applying to the Drug Controller General of India (DCGI) for regulatory approval, a ministry official said.
The proposal follows a meeting in Mumbai, India, in November 2010 between Indian drugmakers and Health Minister Ghulam Nabi Azad.
If deleted, the DCGI will issue approvals only on the grounds of drug quality and efficacy.
The issue will be taken up at the next Drug Testing Advisory Board meeting.
Source: Livemint
Guidelines
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
Reports
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
EMA concept paper towards a tailored clinical approach in biosimilar development
Public consultation for the modification of the biosimilars regulation in Brazil
Comments (0)
Post your comment